Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00041717 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

A Phase 3 study of Spinal Cord Injury and Muscle Spasticity, sponsored by Acorda Therapeutics.

Completed
Registry status
Phase 3
Development phase
213
Enrollment target
20
Study locations

NCT00041717 is a Phase 3 study of Spinal Cord Injury and Muscle Spasticity that has completed, run by Acorda Therapeutics. The registered enrollment target is 213 participants, above the 84-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (154% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00041717, a Phase 3 study of Spinal Cord Injury and Muscle Spasticity, has completed, sponsored by Acorda Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
213 participants
Enrollment target
20
Study locations

Study Summary

Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.

Interventions

  • OTHER Placebo
  • DRUG Fampridine-SR

Study Locations (20)

Illinois

  • Rehabilitation Institute of Chicago - Chicago
  • Advocate Christ Medical Center-Dept. of Physical Medicine & Rehabilitation-EMG - Oak Lawn
  • Springfield Clinic-Neuroscience Institute - Springfield

Massachusetts

  • Spaulding Rehabilitation Hospital - Boston
  • HEALTHSOUTH Braintree Rehabilitation Hospital - Braintree
  • HEALTHSOUTH New England Rehabilitation Hospital - Woburn

California

  • VA Palo Alto Health Care System - Palo Alto
  • Neuro-Therapeutics, Inc - Pasadena

Florida

  • Miami Center to Cure Paralysis at the Univ. of Miami School of Medicine - Miami
  • Rehabilitation Hospital - Sunrise

Alabama

  • Lakeshore Rehabilitation Hospital - Birmingham

Arizona

  • Barrow Neurological Institute - Phoenix

Arkansas

  • Baptist Medical Center - Little Rock

Delaware

  • Neurology Associates, P.A. - Wilmington

Trial Details

FieldValue
Enrollment Target 213 participants
Start Date 2002-07
Est. Completion 2004-05
Phase Phase 3

Sponsor

Acorda Therapeutics

36 total trials

What the Registry Record Tells You About NCT00041717

The ClinicalTrials.gov registry entry for NCT00041717 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 84-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (154% higher). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00041717 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Illinois, Massachusetts, California.

Frequently Asked Questions

What is clinical trial NCT00041717 about?

NCT00041717 is a clinical study titled "Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury". Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrica...

What is the current status of trial NCT00041717?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 213 participants. The study started on 2002-07. Estimated completion is 2004-05.

What conditions does trial NCT00041717 study?

This clinical trial studies the following conditions: Spinal Cord Injury, Muscle Spasticity.

What interventions are being tested in trial NCT00041717?

The interventions under investigation include: Placebo (OTHER), Fampridine-SR (DRUG).

Who is sponsoring clinical trial NCT00041717?

This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00041717 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.